GRS | Jotup

Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO

Retrieved on:

Martedì, Maggio 7, 2024

LYON, France and CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 10th International Congress of the Growth Hormone Research Society (GRS), which is being held May 10-11 in Stockholm, Sweden, the 26th European Congress of Endocrinology (ECE), which is being held May 11-14 in Stockholm, Sweden, and at the 2024 Endocrine Society Meeting (ENDO), which is being held June 1-4 in Boston, Massachusetts.

Key Points:

LYON, France and CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 10th International Congress of the Growth Hormone Research Society (GRS), which is being held May 10-11 in Stockholm, Sweden, the 26th European Congress of Endocrinology (ECE), which is being held May 11-14 in Stockholm, Sweden, and at the 2024 Endocrine Society Meeting (ENDO), which is being held June 1-4 in Boston, Massachusetts.
These presentations cover both of Amolyt’s development programs, eneboparatide in Phase 3 for the treatment of hypoparathyroidism and AZP-3813 in Phase 1 for the treatment of acromegaly.
Details of the presentations are as follows:
10th International Congress of the Growth Hormone Research Society (GRS) – May 10-11, Stockholm, Sweden
Title: Additive Effect of Combined Treatment with the Small Peptide GH Receptor Antagonist, AZP-3813, and the Somatostatin Analog, Octreotide, in Decreasing IGF1 Levels in the Rat
26th European Congress of Endocrinology (ECE) – May 11-14, Stockholm, Sweden
Title: Increased Urinary Excretion of Calcium and Nephrolithiasis: Real-Life Data from the Epi-Hypo Cohort of Hypoparathyroidism Patients
Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel, Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects
Poster Display: 9:40am CEST on Sunday, May 12 to 3:30pm CEST on Tuesday, May 14, 2024
Title: Additive Effect of Combined Treatment with the Small Peptide GH Receptor Antagonist, AZP-3813, and the Somatostatin Analog, Octreotide, in Decreasing IGF1 Levels in the Rat
Title: Increased Bone Fragility Over Time in Women with Chronic Hypoparathyroidism: Real-world Data from the HypoparaNet Italian Cohort
Poster Display: 9:40am CEST on Sunday, May 12 to 3:30pm CEST on Tuesday, May 14, 2024
2024 Endocrine Society Meeting (ENDO) – June 1-4, Boston, Mass.
Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects
Title: Increased Fragility of Bone Over Time in Female Patients with Chronic Hypoparathyroidism: Real-world Data from the Italian Cohort
Title: Enhanced Ability of the Small Peptide GH Receptor Antagonist, AZP-3813, to Decrease IGF1 When Combined with the Somatostatin Analog, Octreotide
Title: Eneboparatide, a Potent Stimulator of Urinary Calcium Reabsorption, Induces Prolonged Renal Cortex Retention and PTH1 Receptor Signalling

Greenway Health Expands Partnership with Client Amidst Successful Billing Transformation

Retrieved on:

Giovedì, Maggio 2, 2024

Greenway Health, American Academy, Infant, Practice, Research, Health, Insurance, AHIMA, Partnership, KLAS, AAPC, GRS, Senior, Health information management, Pediatrics, Ageing, Knowledge, Nursing

TAMPA, Fla., May 2, 2024 /PRNewswire/ -- Greenway Health, a leading health information technology services provider, announced the success of its partnership with Pediatric & Neonatal Specialists following the implementation of Greenway Revenue Services (GRS). Through its ability to address critical billing challenges, Pediatric & Neonatal Specialists expanded its suite of solutions to include Greenway Medical Coding services.

Key Points:

TAMPA, Fla., May 2, 2024 /PRNewswire/ -- Greenway Health , a leading health information technology services provider, announced the success of its partnership with Pediatric & Neonatal Specialists following the implementation of Greenway Revenue Services (GRS).
Through its ability to address critical billing challenges, Pediatric & Neonatal Specialists expanded its suite of solutions to include Greenway Medical Coding services.
As a long-time Greenway client using the Prime Suite EHR and Practice Management solutions, Pediatric & Neonatal Specialists sought to address its billing concerns and staffing shortages with Greenway and its GRS solution.
Greenway Health is a leading health information technology service provider specializing in electronic health records with its flagship Intergy and Prime Suite products.

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

Retrieved on:

Giovedì, Aprile 18, 2024

Congress, European Society of Endocrinology, Growth hormone, PES, LUMO, Abstract, MD, Doctor of Philosophy, GRS, ECE, Transgender hormone therapy, GHS, Growth

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.

Key Points:

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
Pediatric Endocrine Society ( PES ) Annual Meeting, held May 2-5, 2024, in Chicago, IL
Abstract, OraGrowtH210 Trial (Phase 2): Oral LUM-201 Shows Similar Annualized Height Velocity to Daily rhGH in Moderate Pediatric Growth Hormone Deficiency (PGHD) with a 1.6mg/kg/day Dose and a Promising Investigational Safety Record, Andrew Dauber, MD, et al, to be presented in a poster session, Friday, May 3rd, 12:15-1:45 PM CT
The 10th International Congress of the Growth Hormone Research Society ( GRS ), held May 10-11, 2024, in Stockholm, Sweden
Abstract, Approaching the reality of restoring GH secretion and growth with the investigative oral growth hormone secretagogue (GHS) LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD), Peter Clayton, MD, PhD, et al, to be presented in an oral session, Friday, May 10th, 12:00-1:00 PM CET
European Congress of Endocrinology ( ECE ) 2024, held May 11-14, 2024, in Stockholm, Sweden
Abstract, Approaching the reality of restoring GH secretion and growth with the investigative oral growth hormone secretagogue (GHS) LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD), Peter Clayton, MD, PhD, et al, to be presented in an oral session, Sunday, May 12th, 4:20-6:00 PM CET
“We are excited to share additional data analyses from our Phase 2 OraGrowtH Trials with the global endocrine community at these key medical meetings,” said Rick Hawkins, Lumos Pharma’s Chairman and CEO.
“Our Phase 2 data to date have demonstrated that, by augmenting the natural pulsatile secretion of growth hormone, our oral therapeutic candidate, LUM-201, produces comparable growth to injectable rhGH with significantly less exposure to circulating GH.
We believe this information will continue to resonate throughout the endocrine community and that oral LUM-201 could create a paradigm shift in the way PGHD and other growth hormone disorders are treated.”

OrthoLite Announces Extended Patent Protection for its OrthoLite® Hybrid® Technology Line

Retrieved on:

Mercoledì, Aprile 10, 2024

Footwear, Sustainability, Environment, Textiles, Chemicals, Plastics, Fashion, Manufacturing, Retail, Table tennis rubber, Certification, OEM, GRS, RCS, Shoemaking

OrthoLite® , the global leader in comfort and performance footwear insoles, announces that its patent protection has been extended for the speckled appearance of its OrthoLite® Hybrid® Technology line, including Hybrid ®, HybridPlus-Bio ®, and HybridPlus Recycled ®.

Key Points:

OrthoLite® , the global leader in comfort and performance footwear insoles, announces that its patent protection has been extended for the speckled appearance of its OrthoLite® Hybrid® Technology line, including Hybrid ®, HybridPlus-Bio ®, and HybridPlus Recycled ®.
OrthoLite Hybrid® is GRS certified, and blends OrthoLite’s standard inclusion of 5% recycled rubber with a select range of 15% to 43% production waste foam.
To the more than 550 footwear brands OrthoLite works with, the speckled appearance indicates OrthoLite premium quality.
As of April 2, 2024, OrthoLite holds three design patents protecting the visual aesthetics of the Hybrid® line.

Kolon Industries targets the global market with eco-friendly technical textiles through 'Techtextil 2024', a leading international trade fair for textiles

Retrieved on:

Mercoledì, Aprile 24, 2024

Textile, KRX, Fabric discography, GRS, Carbon, Environment, Human, Kolon, PET, Kolon Industries, EPD, Oeko-Tex, Tissue paper

Last year, the company actively implemented digital transformation within the production process when expanding its aramid production to 15,310 tons.

Key Points:

Last year, the company actively implemented digital transformation within the production process when expanding its aramid production to 15,310 tons.
PET non-woven spunbond is expanding its market share in Europe for carpet applications by achieving global eco-friendly certifications such as GRS and EPD.
"Techtextil is a good opportunity to showcase our various textile technologies in the global market," said Chief Operating Officer Choi Yoeng-baeg.
"The European market is especially driving eco-friendly transitions and we will actively demonstrate our sustainable technologies," he added.

Kolon Industries targets the global market with eco-friendly technical textiles through 'Techtextil 2024', a leading international trade fair for textiles

Retrieved on:

Mercoledì, Aprile 24, 2024

Textile, KRX, Fabric discography, GRS, Carbon, Environment, Human, Kolon, PET, Kolon Industries, EPD, Oeko-Tex, Tissue paper

Last year, the company actively implemented digital transformation within the production process when expanding its aramid production to 15,310 tons.

Key Points:

Last year, the company actively implemented digital transformation within the production process when expanding its aramid production to 15,310 tons.
PET non-woven spunbond is expanding its market share in Europe for carpet applications by achieving global eco-friendly certifications such as GRS and EPD.
"Techtextil is a good opportunity to showcase our various textile technologies in the global market," said Chief Operating Officer Choi Yoeng-baeg.
"The European market is especially driving eco-friendly transitions and we will actively demonstrate our sustainable technologies," he added.

Sanuk x Surfrider Launch Ocean-Inspired Earth Day Footwear Collection

Retrieved on:

Martedì, Aprile 23, 2024

Foam, BLOOM, Surfrider Foundation, Weather, Woman, Heart, Partnership, Collection, Breathability, GRS, Surfrider, Adventure, Foundation (nonprofit), Movement

GOLETA, Calif., April 23, 2024 /PRNewswire/ -- In honor of Earth Day, Sanuk®, a division of Deckers Brands (NYSE: DECK), has unveiled an ocean-inspired capsule footwear collection with longtime partner, the Surfrider Foundation, a nonprofit environmental organization dedicated to the protection and enjoyment of our ocean, waves, and beaches for all people. In addition to the collection, Sanuk has elevated the partnership through a donation of $50,000 in 2024 to the Surfrider Foundation in support of its mission to protect your happy places.

Key Points:

The Sanuk x Surfrider capsule collection features four beach-ready styles.
Among them are the latest iterations of Sanuk's best-selling sidewalk surfers: the men's Donny x Surfrider (available in Khaki) and the women's Donna x Surfrider (available in Taupe).
The limited-time Sanuk x Surfrider collection launches today exclusively on Sanuk.com and retails for $50-$70.
For more information about the Sanuk x Surfrider collection, visit www.sanuk.com/sanuk-x-surfrider or follow along on Instagram @sanuk #smileon and @surfrider.

Liberty Mutual Insurance Strengthens Global Capabilities and Operating Model to Embrace Future Opportunities in Asia Pacific and Surety Businesses

Retrieved on:

Mercoledì, Aprile 17, 2024

P&C, Surety, Insurance, Knowledge, GRS, Environment, Liberty Mutual, LII, MENA, LSM, Liberty, Growth

The announcement includes the creation of a new international insurance business division, the unification of two business operations in Asia and the evolution of the company's global surety model. These strategic choices allow GRS to further enable global capabilities through local execution -- all in service of meeting the evolving needs of clients and broker partners.

Key Points:

The announcement includes the creation of a new international insurance business division, the unification of two business operations in Asia and the evolution of the company's global surety model.
GRS will create Liberty International Insurance (LII), which will continue to go to market in Asia Pacific, Europe, Latin America and the UK & MENA under its existing brands, including Liberty Specialty Markets (LSM) and Liberty Insurance.
Matthew Jackson, currently Head of Asia for Liberty Specialty Markets, will be named President, Liberty International Insurance, Asia Pacific.
As a result of this new operating model, Liberty Mutual Surety can better leverage its talent to provide surety customers worldwide with more product expertise and value-added services.

OrthoLite Subsidiary Cirql™ Launches Fully Recyclable Cirql rTPU30 Midsole Innovation Made with 30% Recycled TPU for the Global Footwear Industry

Retrieved on:

Lunedì, Aprile 15, 2024

GRS, TPU, Thwaites, Legislation, Carbon, Certification, Climate, Shoemaking

HO CHI MINH CITY, Vietnam, April 15, 2024 /PRNewswire/ -- OrthoLite®, the global leader of comfort and performance footwear insoles and the company behind Cirql™, a sustainable materials solutions provider for the global footwear industry, today unveils a new midsole foam called Cirql rTPU30. This brand new patented innovation is made with 30-percent post-consumer recycled TPU material and manufactured through a chemical-free, supercritical foaming process. With 16 granted patents and additional patents pending worldwide for its 30% recycled injection foam, Cirql rTPU30 is a scalable and fully recyclable midsole solution that helps footwear brands to reach their climate and sustainability product goals.

Key Points:

This brand new patented innovation is made with 30-percent post-consumer recycled TPU material and manufactured through a chemical-free, supercritical foaming process.
With 16 granted patents and additional patents pending worldwide for its 30% recycled injection foam, Cirql rTPU30 is a scalable and fully recyclable midsole solution that helps footwear brands to reach their climate and sustainability product goals.
"OrthoLite is proud to meet the staggering demand from our 550+ brand partners for more trusted solutions with Cirql rTPU30."
Fully recyclable Cirql rTPU30, along with the fully biodegradable and compostable range of products, round out the Cirql materials solutions for addressing product end of life cycles.

Cupshe Makes Waves with 2024 Annual Recycled Swimwear Collection

Retrieved on:

Venerdì, Aprile 12, 2024

XL, GRS, BSCI, XS, Collection, Water, Carbon footprint, Fashion design

LOS ANGELES, April 12, 2024 /PRNewswire/ -- Global fashion and beachwear e-tailer Cupshe is thrilled to announce the launch of its 2024 Annual Recycled Swim Collection.

Key Points:

LOS ANGELES, April 12, 2024 /PRNewswire/ -- Global fashion and beachwear e-tailer Cupshe is thrilled to announce the launch of its 2024 Annual Recycled Swim Collection.
Featuring 23 swimwear styles, the 2024 Annual Recycled Swim Collection introduces an array of vibrant prints and figure-flattering silhouettes, embodying Cupshe's dedication to fashion-forward yet eco-conscious apparel.
"We are thrilled to build upon the success of our first recycled collection from last year," says Michelle Prisciotta, Brand Manager at Cupshe.
The sustainability of the 2024 Annual Recycled Swim Collection extends beyond materials, as Cupshe has taken meticulous steps to ensure ethical production practices.